Medco/Merck Contract Gets New Spin; Renegotiation May Avert Zocor Impact
Executive Summary
Medco's renegotiation of its rebate agreement with Merck may have allowed the pharmacy benefit manager to avoid loss of rebates accompanying Zocor'slooming patent expiration
You may also be interested in...
Merck Pushes Discount Zocor; Health Plans Are Wary, But Pfizer Is Concerned
The mixed response to Merck's efforts to reach rebate agreements with health plans to place brand Zocor on the lowest cost-sharing tiers of their formularies suggests it is unlikely such a strategy would be broadly adopted by brand firms going forward
Merck Pushes Discount Zocor; Health Plans Are Wary, But Pfizer Is Concerned
The mixed response to Merck's efforts to reach rebate agreements with health plans to place brand Zocor on the lowest cost-sharing tiers of their formularies suggests it is unlikely such a strategy would be broadly adopted by brand firms going forward
Merck Taps Clark As CEO In Nod To Medco Heritage; Gilmartin To Retire
Merck's appointment of Richard Clark to succeed retiring CEO Ray Gilmartin continues the Medco legacy at Merck's senior management level